Comparison · NCT03044314-757d1600
Inhaled Nitric Oxide vs Iloprost: Number of Participants Who Respond After Vasodilator Challenge
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Inhaled Nitric Oxide vs Iloprost: Number of Participants Who Respond After Vasodilator Challenge. Trial comparisons, record NCT03044314-757d1600. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03044314-757d1600
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0435 | 0.00772 | 0.21 | wilson | |
| Risk in group 2 | 0.174 | 0.0698 | 0.371 | wilson | |
| Risk difference, group 1 minus group 2 | -0.13 | -0.331 | 0.0659 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.25 | 0.0302 | 2.07 | log | |
| Odds ratio, group 1 over group 2 | 0.216 | 0.0222 | 2.1 | log | |
| Number needed to treat, for one fewer participant with the outcome on Inhaled Nitric Oxide than on Iloprost | 7.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Inhaled Nitric Oxide | Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.~Iloprost and nitric oxide administration: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated. | 1 | 23 | OG000 |
| Group 2 | Iloprost | Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.~Iloprost and nitric oxide administration: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated. | 4 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Respond After Vasodilator Challenge
- Description
Dichotomize the vasodilator response into responders and nonresponders, based on a 10 mmHg drop in PA pressure and a mean pressure \<40mmHg determined invasively. Receiver operating characteristic (ROC) curves will evaluate the echocardiographic parameters for prediction of vasodilator response.
- Time frame
- Baseline and during vasodilator inhalation, approximately 30 minutes
- Population
- Participants who completed the study. Each participant was analyzed after challenge with iNO and after challenge with iloprost.
Source ClinicalTrials.gov
Trial
- Title
- Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension
- NCT number
- NCT03044314
- Phases
- PHASE4
- Conditions
- Pulmonary Hypertension
- Interventions
- Iloprost and nitric oxide administration
- Lead sponsor
- Duke University
- Results first posted
- 2024-04-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03044314?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03044314-757d1600